Several pathways with documented links to DUX4 activity and FSHD pathology were significantly impacted by one or more treatments: p53 Pathway [18], MYC Targets V1 [23], MYC Targets V2 [23], Inflammatory Response [16], DNA Repair [52], Reactive Oxygen Species Pathway [52], WNT Beta Catenin Signaling [13], and Apoptosis [8,23]. Here, CTNNB1 is linked to Facioscapulohumeral dystrophy.